CB1

CB1 is the main cannabinoid receptor in the brain but is also found in other tissues. CB1 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently reduces cAMP upon activation. This in turn regulates many second messenger pathways.

CB2

CB2 is primarily expressed in the immune cells and tissues of the body. Like CB1, CB2 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently lowers cAMP upon activation. This, in turn, regulates many second messenger pathways.

CBG

CBG is a non-psychoactive cannabinoid with therapeutic potential in cancer, Huntington's Disease, eating disorders, gastrointestinal inflammation, glaucoma and Psoriasis.

TRPM8

TRPM8 is involved in sensory perception.

TRPA1

TRPA1 is best known as a sensor for environmental irritants, pain, cold and stretch.

TRPV3

TRPV3 is one of the non-GPCR-coupled cannabinoid receptors. TRPs are typically involved in pain sensation.

Epilepsy

cannabinoids have excellent therapeutic potential in Epilepsy. In the brain, cannabinoids tend to keep neuronal activity wihtin acceptable boundaries.

Depression

Both plant cannabinoids and the endocannabinoid system have been implicated as risk factors in the development of Depression as well as therapeutic targets to treat Depression.

α2r

α2 receptors are classically known as adrenalin receptors. However, α2 receptors also bind CBG at very high affinity and are therefore also cannabinoid receptors. The interaction between CBG and α2 receptors may be relevant in the treatment of pain and Depression, but more research is required.

COPD

COPD is a chronic lung disease. To date, no cure exists for COPD and therefore most treatments focus on reducing symptoms and suppressing discomfort.